News
09-14-2024, 08:42 AM
Studies reported at ESMO 2024 reveal new groups of women with early-stage endometrial and cervical cancers who gain clinically meaningful benefit from adding immunotherapy to current standard treatments, while a first-in-human study found 'promising' antitumor activity with a novel antibody drug conjugate (ADC) targeting the protein claudin 6 in heavily pretreated patients with ovarian and endometrial cancers.
More... (https://www.news-medical.net/news/20240914/Antibody-drug-conjugate-shows-promise-in-treating-ovarian-and-endometrial-cancers.aspx)
More... (https://www.news-medical.net/news/20240914/Antibody-drug-conjugate-shows-promise-in-treating-ovarian-and-endometrial-cancers.aspx)